Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Paxil product liability claims

Executive Summary

GlaxoSmithKline has settled more than 90% of the product liability claims against Paxil (paroxetine) related to discontinuation symptoms. As part of the settlements, "most" of the pending class action suits concerning discontinuation symptoms are being dismissed, firm says. GSK maintains it did not "admit liability with respect to the allegations in any of the suits." Paxil's labeling was revised in December 2002 to include a precaution concerning "discontinuation of treatment" (1"The Pink Sheet" Aug. 22, 2002, p. 21)...

You may also be interested in...



Paxil TV Ad Case Could Produce Ruling On FDA’s Authority To Regulate Ads

A suit regarding claims in Paxil TV ads could produce a court ruling regarding FDA's authority to regulate advertising

Stalemate Over Virtual Audits In EU As Commission Tells TEAM-NB To Back Off

Notified bodies’ efforts to enhance a harmonized approach to remote audits have failed, raising questions about whether there is any avenue left to get vital devices certified by the 26 May EU MDR deadline.

Amneal’s Generics Business Reinvigorated By New Launches

As Amneal’s generics segment sees significant growth, the company has revealed plans to launch new products and expand in new markets. “We are extremely proud of the progress our company has made since we re-joined as leaders of Amneal,” said Chirag and Chintu Patel, co-CEOs of Amneal.

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel